公开(公告)号：US20230134748A1

公开(公告)日：2023-05-04

申请号：US17980149

申请日：2022-11-03

Applicant: Janssen Biotech, Inc.

Inventor： Peter Hellemans ,  Ming Qi

IPC: A61K39/395 ,  A61K31/573 ,  C07K16/28 ,  A61K38/47 ,  A61P35/00 ,  A61P7/00

Abstract: This disclosure relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid for a time sufficient to treat the hematologic malignancy, wherein the dosing regimen includes a reduction, elimination, or reduction followed by elimination, of corticosteroid administration to the subject. This disclosure also relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid dose of

公开(公告)号：US20230136301A1

公开(公告)日：2023-05-04

申请号：US17979874

申请日：2022-11-03

Applicant: Janssen Biotech, Inc.

Inventor： Peter Hellemans ,  Ming Qi

IPC: C07K16/28 ,  A61K31/573 ,  A61P35/00

Abstract: This disclosure relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid for a time sufficient to treat the hematologic malignancy, wherein the dosing regimen includes a reduction, elimination, or reduction followed by elimination, of corticosteroid administration to the subject. This disclosure also relates to methods of treating a hematologic malignancy, comprising administering to a subject a therapeutically effective amount of an anti-CD38 antibody and a corticosteroid dose of